Company news

Aquestive Therapeutics, Inc. news in 2026

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

November 5, 2026

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 3, 2026

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8: 00 a.m. ET

October 27, 2026

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

October 15, 2026

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

October 14, 2026

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

September 29, 2026

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

September 17, 2026

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

August 10, 2026

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8: 00 a.m. ET

July 29, 2026

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 12, 2026

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8: 00 a.m. ET

May 6, 2026

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

March 29, 2026

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

March 20, 2026

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

March 8, 2026

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

February 25, 2026

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8: 00 a.m. ET

February 24, 2026

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

February 19, 2026

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

February 17, 2026

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

February 1, 2026

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

January 8, 2026

Calls in 2026

Decks in 2026